Affimed (AFMD) said Monday that AFM28 showed "promising" efficacy and safety results evaluating the drug candidate in patients with relapsed/refractory acute myeloid leukemia in an ongoing phase 1 study.
The drug candidate reached a 40% composite complete remission rate at the highest dose level of 300 milligrams in heavily pretreated patients, the company said.
The company said AFM28 showed a "favorable" safety profile, with no signs of neurotoxicity or immune-related side effects seen.
Affimed said the assessment of higher dose levels is being planned, based on the safety profile and the likely dose-effect relationship.
Price: 2.27, Change: -0.06, Percent Change: -2.58
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.